Many healthcare organizations lack mobile tech strategy

Laura Pedulli | | Health Exec | Precision Medicine

Thirty percent of healthcare CIOs report that their organizations have no mobile technology strategy, according to a survey by IT staffing firm Robert Half Technology.

The company had conducted more than 2,300 telephone interviews with CIOs from a random sample of U.S. companies in 23 major metropolitan areas with 100 or more employees.

Of sectors queried, healthcare services had the greatest percentage of respondents reporting no mobile technology strategy. The business services and retail industries had the highest percentages of respondents (65 percent and 63 percent, respectively) using a blend of apps and mobile-friendly web pages.

"Compliance issues have made it difficult for the healthcare industry to move as quickly as other sectors, but as consumer demand for mobile health information grows, formal mobile strategies are a necessary next step,” said John Reed, senior executive director of Robert Half Technology, in a statement.

 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.